Literature DB >> 28742455

Chemoimmunotherapy Is Not Dead Yet in Chronic Lymphocytic Leukemia.

Jennifer R Brown1, Neil E Kay1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28742455     DOI: 10.1200/JCO.2017.72.6810

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  4 in total

Review 1.  Selecting Frontline Therapy for CLL in 2018.

Authors:  Nitin Jain
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2018-11-30

2.  Pentostatin, Cyclophosphamide, and Rituximab Followed by Alemtuzumab for Relapsed or Refractory Chronic Lymphocytic Leukemia: A Phase 2 Trial of the ECOG-Acrin Cancer Research Group (E2903).

Authors:  Sanford Kempin; Zhuoxin Sun; Neil E Kay; Elisabeth M Paietta; Joseph J Mazza; Rhett P Ketterling; Olga Frankfurt; David F Claxton; Joel N Saltzman; Gordan Srkalovic; Natalie S Callander; Gerald Gross; Martin S Tallman
Journal:  Acta Haematol       Date:  2019-07-23       Impact factor: 2.195

3.  Time-to-progression after front-line fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy for chronic lymphocytic leukaemia: a retrospective, multicohort study.

Authors:  Carmen D Herling; Kevin R Coombes; Axel Benner; Johannes Bloehdorn; Lynn L Barron; Zachary B Abrams; Tadeusz Majewski; Jolanta E Bondaruk; Jasmin Bahlo; Kirsten Fischer; Michael Hallek; Stephan Stilgenbauer; Bogdan A Czerniak; Christopher C Oakes; Alessandra Ferrajoli; Michael J Keating; Lynne V Abruzzo
Journal:  Lancet Oncol       Date:  2019-09-30       Impact factor: 41.316

4.  Deep targeted sequencing of TP53 in chronic lymphocytic leukemia: clinical impact at diagnosis and at time of treatment.

Authors:  Christian Brieghel; Savvas Kinalis; Christina W Yde; Ane Y Schmidt; Lars Jønson; Michael A Andersen; Caspar da Cunha-Bang; Lone B Pedersen; Christian H Geisler; Finn C Nielsen; Carsten U Niemann
Journal:  Haematologica       Date:  2018-12-04       Impact factor: 9.941

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.